XVIVO Elevates CFO to Lead Global Strategy as It Targets U.S. Growth

Xvivo Perfusion AB ( (SE:XVIVO) ) has provided an update.

XVIVO Perfusion AB has reassigned its Chief Financial Officer, Kristoffer Nordström, to the newly created position of Senior Vice President Corporate Strategy & Business Development, effective April 1, 2026, while he remains on the executive management team. The new global role, with a particular focus on the U.S. market and leadership of the U.S. service organization, is designed to support a wave of upcoming product launches in heart, kidney, and liver transplantation and to strengthen the company’s commercial presence as it invests for growth, with a search underway for a new CFO.

XVIVO’s decision to redeploy a seasoned financial executive into a business-focused strategic role underscores the importance of the U.S. market in its growth agenda. The move signals a sharpening of corporate strategy and operational support around forthcoming transplant technology launches, which could reinforce the company’s competitive position in organ preservation and benefit stakeholders through a stronger U.S. organization and potentially accelerated commercialization.

The most recent analyst rating on (SE:XVIVO) stock is a Hold with a SEK198.00 price target. To see the full list of analyst forecasts on Xvivo Perfusion AB stock, see the SE:XVIVO Stock Forecast page.

More about Xvivo Perfusion AB

XVIVO Perfusion AB is a Swedish medical technology company focused exclusively on extending the life of major organs such as heart, kidney, and liver to enable more successful transplants. Founded in 1998 and listed on Nasdaq Stockholm under the ticker XVIVO, the company provides solutions that support transplant teams and researchers globally, with headquarters in Gothenburg and operations across two continents.

Average Trading Volume: 182,584

Technical Sentiment Signal: Sell

Current Market Cap: SEK5.75B

For an in-depth examination of XVIVO stock, go to TipRanks’ Overview page.